General Information of the Cell Line
Cell Line ID
CL000303
Cell Line Name
AN3-CA
Synonyms
AN3_CA
AN3 CA
AN3 Ca
AN3CA
AN-3
AN3
Acanthosis Nigricans 3rd attempt-CArcinoma
Category
Cancer cell line
Organism
Homo sapiens (Human)
Cellosaurus ID
CVCL_0028
Tissue Information
Lymph node
Disease
Acanthosis nigricans--NCIt; C7359; Endometrial adenocarcinoma (NCIt: C26687)
Endometrial adenocarcinoma (NCIt: C7359)
Map of Molecular Bioactivity Related to the Cell Line
Map of Molecular Bioactivity Related to the Cell Line

Cell Line
Protein
Compound

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Cell Line
Protein ID: PT00845, RAC-alpha serine/threonine-protein kinase
Compound ID Compound Name Compound Formula
CP0376695
N-[[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]-3-fluorobenzamide
   Show/Hide
C33H26FN7O2
 3
1
IC50 = 44 nM
   TI
   LI
   LO
   TS
2
IC50 = 45 nM
   TI
   LI
   LO
   TS
3
IC50 = 220 nM
   TI
   LI
   LO
   TS
CP0405066
N-[[4-[2-(2-aminopyridin-3-yl)-6-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]-3-fluorobenzamide
   Show/Hide
C30H22FN7O
 3
1
IC50 = 46 nM
   TI
   LI
   LO
   TS
2
IC50 = 49 nM
   TI
   LI
   LO
   TS
3
IC50 = 820 nM
   TI
   LI
   LO
   TS
CP0389476
2-[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]-N-phenylacetamide
   Show/Hide
C33H27N7O2
 3
1
IC50 = 47 nM
   TI
   LI
   LO
   TS
2
IC50 = 49 nM
   TI
   LI
   LO
   TS
3
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0453697
2-[4-[2-(2-aminopyridin-3-yl)-5-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]-N-phenylacetamide
   Show/Hide
C30H23N7O
 3
1
IC50 = 51 nM
   TI
   LI
   LO
   TS
2
IC50 = 69 nM
   TI
   LI
   LO
   TS
3
IC50 = 2500 nM
   TI
   LI
   LO
   TS
CP0441192
N-[[4-[2-(2-aminopyridin-3-yl)-6-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C30H23N7O
 3
1
IC50 = 80 nM
   TI
   LI
   LO
   TS
2
IC50 = 91 nM
   TI
   LI
   LO
   TS
3
IC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0397465
2-[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]-N-(3-fluorophenyl)acetamide
   Show/Hide
C33H26FN7O2
 3
1
IC50 = 90 nM
   TI
   LI
   LO
   TS
2
IC50 = 260 nM
   TI
   LI
   LO
   TS
3
IC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0376644
N-[[4-[2-(2-aminopyridin-3-yl)-5-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]-3-fluorobenzamide
   Show/Hide
C30H22FN7O
 3
1
IC50 = 95 nM
   TI
   LI
   LO
   TS
2
IC50 = 340 nM
   TI
   LI
   LO
   TS
3
IC50 = 2100 nM
   TI
   LI
   LO
   TS
CP0376692
N-[[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C33H27N7O2
 3
1
IC50 = 110 nM
   TI
   LI
   LO
   TS
2
IC50 = 170 nM
   TI
   LI
   LO
   TS
3
IC50 = 840 nM
   TI
   LI
   LO
   TS
CP0441194
N-[[4-[2-(2-aminopyridin-3-yl)-6-phenylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C31H24N6O
 3
1
IC50 = 160 nM
   TI
   LI
   LO
   TS
2
IC50 = 980 nM
   TI
   LI
   LO
   TS
3
IC50 = 1100 nM
   TI
   LI
   LO
   TS
CP0397469
N-[[4-[2-(2-aminopyridin-3-yl)-5-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C30H23N7O
 3
1
IC50 = 1400 nM
   TI
   LI
   LO
   TS
2
IC50 = 3200 nM
   TI
   LI
   LO
   TS
3
IC50 = 4200 nM
   TI
   LI
   LO
   TS
CP0024409
2-[4-[2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]-N-phenylacetamide
   Show/Hide
C25H20N6O
 2
1
IC50 = 2500 nM
   TI
   LI
   LO
   TS
2
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0389516
N-[[4-[2-(2-aminopyridin-3-yl)-6-bromoimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C25H19BrN6O
 2
1
IC50 = 2500 nM
   TI
   LI
   LO
   TS
2
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0397464
N-[[4-[2-(2-aminopyridin-3-yl)-6-cyclopentylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C30H28N6O
 3
1
IC50 = 3700 nM
   TI
   LI
   LO
   TS
2
IC50 = 9400 nM
   TI
   LI
   LO
   TS
3
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0022681
N-[[4-[2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C25H20N6O
 2
1
IC50 = 5600 nM
   TI
   LI
   LO
   TS
2
IC50 > 10000 nM
   TI
   LI
   LO
   TS
CP0389475
N-[[4-[2-(2-aminopyridin-3-yl)-5-phenylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C31H24N6O
 1
1
IC50 > 10000 nM
   TI
   LI
   LO
   TS
Cell Viability or Cytotoxicity Assay
Compound ID Compound Name Compound Formula
CP0024409
2-[4-[2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]-N-phenylacetamide
   Show/Hide
C25H20N6O  1
1
IC50 = 70000 nM
   TI
   LI
   LO
   TS
CP0112599
US8569511, 2
   Show/Hide
C23H22F2N6O2  1
1
IC50 < 30 nM
   TI
   LI
   LO
   TS
CP0376644
N-[[4-[2-(2-aminopyridin-3-yl)-5-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]-3-fluorobenzamide
   Show/Hide
C30H22FN7O  1
1
IC50 = 10000 nM
   TI
   LI
   LO
   TS
CP0376692
N-[[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C33H27N7O2  1
1
IC50 = 1500 nM
   TI
   LI
   LO
   TS
CP0376695
N-[[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]methyl]-3-fluorobenzamide
   Show/Hide
C33H26FN7O2  1
1
IC50 = 2000 nM
   TI
   LI
   LO
   TS
CP0389476
2-[4-[5-(3-acetamidophenyl)-2-(2-aminopyridin-3-yl)imidazo[4,5-b]pyridin-3-yl]phenyl]-N-phenylacetamide
   Show/Hide
C33H27N7O2  1
1
IC50 = 2100 nM
   TI
   LI
   LO
   TS
CP0389516
N-[[4-[2-(2-aminopyridin-3-yl)-6-bromoimidazo[4,5-b]pyridin-3-yl]phenyl]methyl]benzamide
   Show/Hide
C25H19BrN6O  1
1
IC50 = 60000 nM
   TI
   LI
   LO
   TS
CP0453697
2-[4-[2-(2-aminopyridin-3-yl)-5-pyridin-3-ylimidazo[4,5-b]pyridin-3-yl]phenyl]-N-phenylacetamide
   Show/Hide
C30H23N7O  1
1
IC50 = 8800 nM
   TI
   LI
   LO
   TS
Protein family and CMB statistics Related to the Cell Line
Cell Lines Derived from the same Tissue Source (Lymph node)
Cell Line Name Organism Disease
A2058 Homo sapiens (Human) Amelanotic melanoma
LOX-IMVI Homo sapiens (Human) Amelanotic melanoma
SW620 Homo sapiens (Human) Colon adenocarcinoma
SW620/AD300 Homo sapiens (Human) Colon adenocarcinoma
LoVo Homo sapiens (Human) Colon adenocarcinoma
SK-MEL-5 Homo sapiens (Human) Cutaneous melanoma
SU-DHL-5 Homo sapiens (Human) Diffuse large B-cell lymphoma germinal center B-cell type
HOC313 Homo sapiens (Human) Floor of mouth squamous cell carcinoma
HGC-27 Homo sapiens (Human) Gastric carcinoma
NUGC-4 Homo sapiens (Human) Gastric signet ring cell adenocarcinoma
NCI-H1993 Homo sapiens (Human) Lung adenocarcinoma
PC-9 Homo sapiens (Human) Lung adenocarcinoma
NCI-H838 Homo sapiens (Human) Lung adenocarcinoma
NCI-H1568 Homo sapiens (Human) Lung adenocarcinoma
PC9-DRH Homo sapiens (Human) Lung adenocarcinoma
NCI-H2009 Homo sapiens (Human) Lung adenocarcinoma
NCI-H1299 Homo sapiens (Human) Lung large cell carcinoma
NCI-H1155 Homo sapiens (Human) Lung large cell carcinoma
NCI-H292 Homo sapiens (Human) Lung mucoepidermoid carcinoma
HBL-2 [Human mantle cell lymphoma] Homo sapiens (Human) Mantle cell lymphoma
MNT-1 Homo sapiens (Human) Melanoma
JR8 Homo sapiens (Human) Melanoma
MM96L Homo sapiens (Human) Melanoma
WM3629 Homo sapiens (Human) Melanoma
L3.6pl Homo sapiens (Human) Pancreatic adenosquamous carcinoma
LNCaP Homo sapiens (Human) Prostate carcinoma
LAPC-4 Homo sapiens (Human) Prostate carcinoma
LNCaP-AR Homo sapiens (Human) Prostate carcinoma
LNCaP C4-2 Homo sapiens (Human) Prostate carcinoma
MR49F Homo sapiens (Human) Prostate carcinoma
LNCaP-hr Homo sapiens (Human) Prostate carcinoma
LNCap-ARR2PB-eGFP Homo sapiens (Human) Prostate carcinoma
Th17 Mus musculus (Mouse) -